Application Detail

Status

Open

Description of Medical Service

ImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab

Description of Medical Condition

unresectable mesothelioma

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application form (PDF 247 KB)
Application form (Word 536 KB)

PICO Confirmation

PICO Confirmation (PDF 725 KB)
PICO Confirmation (Word 210 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

8 December 2016

ESC

-

MSAC

-